Lou Carlozo

Lou Carlozo

InvestorPlace Contributor

Lou Carlozo is Editor In Chief at Qwoted, a source platform for finance journalists, and host/creator of Bankadelic, a financial services podcast. Through 2019, he served as managing editor at the Bank Administration Institute and an investment writer at U.S. News & World Report. A Pulitzer Prize finalist (team reporting), his work has appeared in Reuters, the Chicago Tribune, Los Angeles Times, Yahoo Finance, MSN and publications across the world; his multi-media journalism credits include BBC radio, Investigation Discovery TV, AOL and an Archie cartoon where he appeared as himself. Lou is also a professional musician, producer/composer and recording studio owner. He resides in Chicago with his wife and two children.

Recent Articles

For Biopharma Ocugen, Think Speculation In Small Doses

By Lou Carlozo, InvestorPlace Contributor

While Ocugen is unprofitable and in bad need of cash, OCGN stock could soar if its eye disease therapies see clinical success.

Genius Brands International Hardly a Marvel

By Lou Carlozo, InvestorPlace Contributor

GNUS stock could see a bump in time from its joint venture to create Stan Lee Universe. But some investors feel the deal was over-hyped.

Avoiding Genius Brands International Is a No-Brainer

By Lou Carlozo, InvestorPlace Contributor

Though Genius Brands International is devoted to kids entertainment, investing in GNUS stock is anything but child's play.

At This Point, iBioPharma Is a Flash in the Pandemic

By Lou Carlozo, InvestorPlace Contributor

Sure, iBio hopes to win the Covid-19 vaccine race, but right now, IBIO stock investors aren't benefiting from the pursuit.

Nokia Stock Will Finish the Year Strong

By Lou Carlozo, InvestorPlace Contributor

Despite the challenges of 2020, Nokia stock has benefited from two strong quarters and the unexpected woes of Huawei Technologies.

Load More